Differential effects of growth hormone therapy in malnourished hemodialysis patients.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Several factors such as metabolic acidosis, hyperparathyroidism, and insulin as well as growth hormone (GH) resistance may lead to enhanced protein catabolism.

Recombinant human growth hormone (rhGH) has been proposed as treatment of malnutrition because of its anabolic effects.

Who Took Part

The study group was 19 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

In the present placebo-controlled, double blind study, the effects of three months of rhGH therapy on nutritional and anthropometric parameters, on bone metabolism and bone mineral density (BMD), as well as on polymorphonuclear leukocyte (PMNL) function and quality of life (QoL) were evaluated in 19 malnourished hemodialysis patients (10 females and 9 males) with a mean age of 59.3 +/- 13.4 years.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Exogenous HGH, sermorelin & older GHRPs (why they're passed over), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

What Was Measured

PubMed files the paper under topics including Anthropometry, Bone Density, Bone Remodeling, Human Growth Hormone, Insulin-Like Growth Factor I, Lumbar Vertebrae and Neutrophils.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (Kidney international), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.